logo
logo

Ava­lyn Phar­ma raises $100 million in a Series D round to develop inhaled medicines for pulmonary fibrosis, targeting effective delivery to the lungs.

Jul 22, 2025•13 days ago

Amount Raised

$100 Million

Round Type

series d

CambridgeHealth CareBiotechnology

Description

Ava­lyn Phar­ma has secured $100 million in a Series D funding round. The funding will be used to advance their inhaled pulmonary fibrosis medicines. The company aims to ensure the drugs reach the optimal location within the lung for effectiveness. This investment marks a significant step in their development process.

Company Information

Company

Avalyn

Location

245 First Street, 18th Floor

Cambridge, Massachusetts, United States

About

Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech